Therapeutic approaches in malignant mesothelioma.
D000477:Alkylating Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000627:therapeutic use; D006048:Gold Colloid, Radioactive / Q000627:therapeutic use; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008727:Methotrexate / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D010166:Palliative Care; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011879:Radiotherapy Dosage; D013852:Thiotepa / Q000627:therapeutic use
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D006048:Gold Colloid, Radioactive; D009588:Nitrogen Mustard Compounds; D010761:Phosphorus Radioisotopes; D003609:Dactinomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D013852:Thiotepa; D005472:Fluorouracil; D008727:Methotrexate